Mission Pharmacal Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: San Antonio TX United States (1946)

Organization Overview

First Clinical Trial
2005
NCT00229216
First Marketed Drug
1971
urea
First NDA Approval
1983
acetohydroxamic acid
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MISSION PHARMA | MISSION PHARMACAL CO

Active Ingredients

Marketed Drugs (12)

acetohydroxamic acid (1983 NDA)

alendronic acid (fosamax) (2012)

carbinoxamine maleate (clistin) (2011)

cellulose (1982)

folic acid (1981)

homatropine (1979)

potassium citrate (urocit-k) (1985 NDA)

potassium iodide (thyro-block) (2016)

prednisolone (hydeltra) (2010)

tinidazole (tindamax) (2004)

tiopronin (thiola) (1988 NDA)

urea (1971)

Drugs in Phase 3 Trials (1)

tinidazole (tindamax) (2 trials)

Drugs in Phase 2 Trials (2)

mpc-5971 (1 trial)

mpc-shrc (1 trial)

Indications

Approved Indications


 

Cystinuria

Urinary Tract Infections

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 2)

Kidney Calculi (Phase 2)

Nephrolithiasis (Phase 2)

Urinary Tract Infections (Phase 2)

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3